Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 14/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1441164 | 0.84 | ALDH1A1 (0.40) | ALDH1A1TSHRHSD17B10GRM2HDAC3 | |
| SCHEMBL21595152 | 0.81 | HDAC3 (0.39) | ALDH1A1TSHRHSD17B10HDAC3HDAC4 | |
| SCHEMBL12263459 | 0.80 | HTR2C (0.44) | NPC1ALDH1A1 | |
| SCHEMBL23863507 | 0.79 | HDAC3 (0.41) | CNR2ALDH1A1TSHRHSD17B10HDAC3 | |
| SCHEMBL1346196 | 0.78 | PKM (0.46) | CNR2NPC1RAB9AGRM2 | |
| SCHEMBL21130547 | 0.78 | HDAC3 (0.40) | CNR2NPC1RAB9AALDH1A1TSHR | |
| SCHEMBL9453861 | 0.77 | EGLN1 (0.53) | CNR2NPC1RAB9AALDH1A1GRM2 | |
| SCHEMBL1129736 | 0.77 | HDAC3 (0.40) | CNR2ALDH1A1TSHRHSD17B10HDAC3 | |
| SCHEMBL27739326 | 0.76 | HDAC3 (0.35) | ALDH1A1TSHRHSD17B10HDAC3HDAC4 | |
| SCHEMBL21594935 | 0.76 | ALDH1A1 (0.35) | NPC1RAB9AALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-04-25 | — | — | US | disclosed |
| CN-112888696-B | Exonuclease inhibitors and methods of use thereof | 德琪医疗有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| US-11078228-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-112888696-A | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2021-06-01 | — | — | CN | disclosed |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2019-12-26 | — | — | US | disclosed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140005400-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8552024-B2 | Azacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2603510-A1 | NEW AZACYCLIC COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020035-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CNR2 158/4885NPC1 885/4885RAB9A 3127/4885 |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CNR2 158/4885NPC1 885/4885RAB9A 3127/4885 |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CNR2 158/4885NPC1 885/4885RAB9A 3127/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CNR2 158/4885NPC1 885/4885RAB9A 3127/4885 |
| US-20140005400-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | CNR2 854/4885NPC1 620/4885RAB9A 2930/4885 |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CNR2 158/4885NPC1 885/4885RAB9A 3127/4885 |
| US-11078228-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CNR2 158/4885NPC1 885/4885RAB9A 3127/4885 |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | CNR2 854/4885NPC1 620/4885RAB9A 2930/4885 |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | CNR2 854/4885NPC1 620/4885RAB9A 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.